chronic thromboembolic pulmonary hypertension
Respiratory · 2014–2016
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| riociguat Treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent CTEPH subsequent to pulmonary endarterectomy (PEA) in adult… | Mar 2016 | Recommended with restriction | 1 individuals |
| riociguat Inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent CTEPH subsequent to pulmonary endarterectomy (PEA). | Jul 2015 | Not recommended | 12 individuals |
| riociguat Inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary endarterectomy in patients with WHO Functional Class… | Nov 2014 | Recommended with restriction | 3 individuals Pulmonary Hypertension Association Australia |
Who spoke
Pulmonary Hypertension Association Australia
What the PBS pays
$11M in government benefit over 2024–25, across 3,573 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| riociguat | $11.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.